The new approval is for certain patients with ER-positive, HER2-negative advanced breast cancer who have received at least one line of endocrine therapy. The U.S. Food and Drug Administration (FDA) has approved imlunestrant (Inluriyo)...
MRI surveillance for brain metastases helps preserve cognition in small cell lung cancer, and an AACR report calls for sustained research funding.
The September Editors’ Picks from AACR's peer-reviewed journals include insights into cancer evolution in leukemia, a strategy for overcoming drug resistance, the impacts of the COVID-19 pandemic on cancer care, an investigational treatment for...
Aminolevulinic acid hydrochloride is given as a topical gel in combination with light-based therapy. The U.S. Food and Drug Administration (FDA) has approved aminolevulinic acid hydrochloride (Ameluz) for the treatment of superficial basal cell...
Cancer care aid enrollments for people near the World Trade Center site tripled in recent years, and the FDA approved an oral SERD for ESR1-mutated breast cancer.
Tsedey Tsegaye had her sights on a career in health communication—until a civil war upended her life. A scholarship from AACR CEO Margaret Foti, through the Margaret Foti Foundation, gave her another chance to...
A recently approved drug that targets RAS proteins meaningfully improves outcomes for people with this difficult-to-treat cancer.
Sevabertinib received accelerated approval as first-line treatment for some lung cancers with HER2 activating mutations. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to sevabertinib (Hyrnuo), for the treatment of adults...
In memory of those who lost their lives or families as a result of what happened on September 11, 2001, this edition of Cancer Research Catalyst reviews the effects of the attacks and showcases...
The approval marks the first ctDNA-guided cancer therapy. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to camizestrant (Etcamah) in combination with a CDK4/6 inhibitor (either abemaciclib [Verzenio], palbociclib [Ibrance], or...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More